Geron Stifel 2026 Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Harout Semerjian, and we have Joseph Eid, who heads up the R&D effort of the company. We're just going to have kind of a casual discussion. If anyone has a question, feel free to raise your hand. We'll get you acknowledged and hopefully get your question answered. Harout, Joseph, thanks so much for coming today, and any opening comments you'd like to make before we jump into Q&A?
Well, thank you, Steve, and thank you to Stifel for the opportunity to present our story. Our story continues to emerge as a commercial company. Last week, we have reported our fourth quarter of back-to-back growth. We're quite excited that our net revenue has now cracked the $60 million for the quarter, so that's an internal milestone we were very happy to see, all while being financially disciplined as well as we execute on our plan and make sure that we set up ourselves not just for short-term growth, but also long-term growth. So, from that side, Steve, our U.S. business is on a very good trajectory, stabilized in terms of growth. We've demonstrated account growth. We've demonstrated the right patients mix. I'm sure we're going to get into that. Overall, that's good. On top of that, we've also given some additional color in terms of how we're thinking and executing on our ex-U.S. strategy, starting with Germany as well.
Overall, healthy growth, and I'm sure we're going to get into that.
Okay. Maybe we can just jump right into RYTELO and focus on lower-risk MDS specifically. I know you've been in this seat now for what, 12 or 15 months or so. Where do you think you've made the most commercial progress, and where do you think there's still significant improvements to be made? I guess, what are the strategies right now that you're emphasizing in an effort to try to drive uptake?
Yeah. No, I have been in the role since August 2025.
Okay. I mean, if you think about the arc of our strategy, in the beginning, it was really about what would it take for us to grow RYTELO in the U.S.?
That was really our first focus area, and we had to start from a point where we actually simplified our operations in the U.S., and that resulted in the RIF that we had announced in December 2025. Since then, we have not really missed a beat in terms of going rapidly for a reset in our way of how we actually engage with the marketplace, starting with our academic medical centers, but really keeping an eye on the ball on the community-based physicians, because 80% of low-risk MDS continues to be treated in the community. This is the disease of the elderly and of the community.
When we really engage with the academic medical centers, given that in the U.S., we did not really have a lot of advocates, they were not part of the IMerge program, and so we really expanded our ability to engage with that medical expert population. Now with our more revised strategy in the community, focusing on the high-volume accounts, focusing on a simplified message, really focused on the second-line patient population, we are very happy to say that in the last couple of quarters, we have been reporting now that predominantly our growth is coming from the community. I think that transition from first resetting the company in a way that it makes it very actionable, to the academic medical centers, the engagement in the U.S., which happened now after the launch, but it did happen.
Third, really making sure that we are shifting towards the community and how we engage with them. I think that is kind of what is really fueling our growth, and we were able to demonstrate that over the last four quarters now.
back to back, with not just the top-line growth, demand growth, expansion of the number of accounts ordering RYTELO, and then the patient population that's coming from first line, second line, rather than just the late-line patients, which we were getting in the beginning.
Okay. I know sales are kind of ultimately the barometer of progress here. But what are some of the kind of the key commercialization metrics that you're focusing on internally in an effort to really kind of gauge how some of these strategic initiatives and messaging has been resonating with prescribers?
Yeah. I mean, sales obviously is the ultimate barometer, but it's a lagging indicator in some ways, right? That's why we gave additional color in terms of where that's coming from. Starting from saying that predominantly our growth is coming from the community, that's an important area in our opinion, because it is an indicator that 80% of the patient population that is in the community, we're making headways around that. That's why we have qualitatively as well mentioned this year or in the last quarter that we see RYTELO grow for many years to come, because of the fact that we're able to now make inroads on the community setting. That's one. Then the second is, well, how much is our expansion of accounts that are ordering RYTELO?
Now we've reached 1,700 accounts, which is a very important aspect because every quarter, we're growing another, call it 100 to 200 accounts, new accounts that have never ordered RYTELO before and now are ordering RYTELO. It doesn't mean every account, 1,700, are all active all the time. It just means that that pool is continuously expanding over time, which is really great. Then the third one is, which type of patients are we getting? In oncology, hematology, as you know, Steve, a lot of the first wave of patients you get are really the tough-to-treat patient populations. Patients who've been on multiple different therapies, haven't really been able to get benefit or relapsed after a while, and now physicians are trying them on this new kid on the block. That happens in the beginning, but you can't really bet on that.
You really want to see the business move into the indications that we're approved on, which is in the second-line patient population. That's why one of the early indicators as well that we give is how much of our business is coming from that first line, second line, and that number has continuously increased. Currently, it stands at 36%, so more than one-third of our patient population is coming from that first line, second line, and that has been growing 1%-2% point every quarter.
with a 12-month look-back KPI.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
